Read this company snapshot
Daily valuation snapshot
Arcutis Biotherapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $26.58
- Market capitalization (USD)
- $3,340,892,323.38
- Price / earnings (TTM)
- 117.15
- Price / book
- 15.15
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ARQT in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ARQT in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ARQT with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $26.58 |
| Market capitalization (USD) | $3,340,892,323.38 |
| Price / earnings (TTM) | 117.15 |
| Price / book | 15.15 |
No matching rows. Clear the filter to see all records.
Read ARQT's valuation metrics
Company size
Arcutis Biotherapeutics, Inc. Common Stock's recorded market capitalization is $3,340,892,323.38. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
ARQT's recorded P/E is 117.15: about $117.15 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
ARQT's recorded price-to-book ratio is 15.15. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Arcutis Biotherapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about ARQT. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ARQT's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.